目的 探討司美格魯肽聯(lián)合阿卡波糖治療超重及肥胖2型糖尿病的臨床療效。方法 選取2021年8月—2022年8月天津市北辰醫(yī)院收治的2型糖尿病患者100例，隨機(jī)分為對(duì)照組（50例）和治療組（50例）。對(duì)照組患者口服阿卡波糖片，起始劑量為50 mg/次，3次/d，隨后逐漸增加至100 g/次，3次/d。在對(duì)照組的基礎(chǔ)上，治療組皮下注射司美格魯肽注射液，1.0 mg/次，1次/周。兩組患者用藥12周。觀察兩組患者臨床療效，比較治療前后兩組患者糖化血紅蛋白（HbAlc）、空腹血糖（FBG）、餐后2 h血糖（2 h PG）、空腹胰島素（FINS）、三酰甘油（TC）、膽固醇（TG）、體質(zhì)量指數(shù)（BMI）、胰島素抵抗值數(shù)（HOMA-IR）、白細(xì)胞介素-6（IL-6）、白細(xì)胞介素-1β（IL-1β）、脂蛋白相關(guān)磷脂酶A2（Lp-PLA2）和C反應(yīng)蛋白（CRP）水平。結(jié)果 治療后，治療組患者臨床有效率為96.00%，明顯高于對(duì)照組（84.00%，P＜0.05）。治療后，兩組患者HbAlc、FBG、2 h PG、FINS、TC、TG、BMI、HOMA-IR、IL-6、IL-1β、Lp-PLA2和CRP水平均明顯降低（P＜0.05），且治療后治療組這些指標(biāo)水平均明顯低于對(duì)照組（P＜0.05）。結(jié)論 司美格魯肽聯(lián)合阿卡波糖治療超重及肥胖2型糖尿病效果確切，可有效改善胰島素的抵抗，降低超重及肥胖患者糖代謝水平，并可減弱機(jī)體炎癥反應(yīng)狀態(tài)。

Objective To investigate the efficacy of semaglutide combined with acarbose in treatment of type 2 diabetes of overweight and obese. Methods Patients (100 cases) with type 2 diabetes of overweight and obese in Tianjin Beichen Hospital from August 2021 to August 2022 were randomly divided into control (50 cases) and treatment (50 cases) group. Patients in the control group were po administered with Acarbose Tablets, the initial dose was 50 mg/time, three times daily, and the following dose was increased to 100 mg/time, three times daily. Patients in the treatment group were subcutaneous injection administered with Semaglutide Injection on the basis of the control group, 1 mg/time, once weekly. Patients in two groups were treated for 12 weeks. After treatment, the clinical evaluation was evaluated, and the levels of HbAlc, FBG, 2 h PG, FINS, TC, TG, BMI, HOMA-IR, IL-6, IL-1β, Lp-PLA2 and CRP in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 96.00%, which was significantly higher than that of the control group (84.00%, P < 0.05). After treatment, the levels of HbAlc, FBG, 2 h PG, FINS, TC, TG, BMI, HOMA-IR, IL-6, IL-1 β, Lp-PLA2 and CRP were significantly decreased in two groups (P < 0.05), and the levels of these indexes in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion The effect of acarbose combined with semaglutide in treatment of type 2 diabetes of overweight and obese is accurate, it can effectively improve insulin resistance, reduce the level of glucose metabolism in overweight and obese patients, and reduce the state of inflammatory reaction.

R977

天津市北辰區(qū)科技發(fā)展計(jì)劃項(xiàng)目(SHGY2020010)